Jacobs Levy Equity Management, Inc Amylyx Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.2 Billion
- Q2 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 589,111 shares of AMLX stock, worth $2.92 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
589,111Holding current value
$2.92 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AMLX
# of Institutions
139Shares Held
46.5MCall Options Held
226KPut Options Held
909K-
Vanguard Group Inc Valley Forge, PA4.22MShares$21 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.34MShares$16.6 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$13.2 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.61MShares$12.9 Million0.0% of portfolio
-
Abrdn PLC1.97MShares$9.78 Million0.01% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $290M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...